证券代码：000930 证券简称：中粮科技 公告编号：2024-027 中粮生物科技股份有限公司 关于公司 2024 年度向部分金融机构申请授信、融资事项的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 4.2024 年度公司向交通银行股份有限公司蚌埠市分行申请不超过人民币 6 亿元综合授信项下融资（含本外币），业务品种包括但不限于流动资金贷款、法 人账户透支、贸易融资、融资性保函、衍生产品业务等，信用方式，期限 1 年（含）。 5.2024 年度公司向中国银行股份有限公司蚌埠分行申请最高不超过人民币 3 亿元流动资金贷款、最高不超过人民币 1 亿元法人账户透支、最高不超过人民 币1.95亿元本外币贸易融资和最高不超过500万元交易对手信用风险专项额度， 信用方式，期限均为 1 年（含）。 6.2024 年度公司向中国农业发展银行股份有限公司蚌埠市分行申请最高不 超过 4 亿元流动资金贷款，信用方式，期限 1 年（含）。 7.2024 年度公司向中信银行股份有限公司蚌埠市分行申请不超过人民币 1.5 亿元综合授信项下融资，信用方式，期限 1 年（含）。 为满 ...

中粮生物科技股份有限公司 独立董事关于相关事项的事前确认函 我们事前收到中粮生物科技股份有限公司提交的《关于公司 2024 年度日常 关联交易预计情况的议案》《关于公司 2024-2025 年度向中粮财务有限责任公司 申请 41 亿元综合授信的议案》等相关材料。我们认真审阅了有关材料，公司管 理层就有关事项与我们进行了充分的沟通。我们认为： 对上述议案，公司董事会在审议时需依据《深圳证券交易所股票上市规则》 和《公司章程》的规定，不应出现损害公司、股东及非关联方利益的情形。 1 （此页无正文，为中粮生物科技股份有限公司独立董事关于相关事项的事前确 认函独立董事签字页） 陈国强 李世辉 张念春 一、关于公司 2024 年度日常关联交易事项的事前审核意见 公司 2024 年度日常关联交易预计事项，符合公司利益和股东利益最大化原 则，公司与关联企业之间的业务往来按一般市场经营规则进行，与其他业务往来 企业同等对待。公司与关联企业之间不可避免的关联交易，遵照公平、公正的市 场原则，交易价格将按照市场规律，以市场同类交易标的的价格为依据。交货、 付款均按相关合同条款执行。公司与关联方交易价格依据市场公允价格确定，符 合 ...

中粮生物科技股份有限公司 | 应出席 | 现场出席 | 以通讯方式参 | 委托出席 | 缺席 | 是否连续两次未 | | --- | --- | --- | --- | --- | --- | | 次数 | （次） | 加会议次数 | 次数 | 次数 | 亲自出席会议 | | 8 | 1 | 7 | 0 | 0 | 否 | 2023年本人任职期间，公司共召开8次董事会，本人均参加会议审议会议的 各项议案，对有关议案进行表决，并对有关事项发表独立意见。本人注重运用自 身专长，以独立客观的角度，对有关事项做出客观、公正的判断，不受公司主要 股东和公司管理层的影响，切实维护公司和中小股东的利益。 二、2023年度发表独立意见情况 2023 年，本人根据中国证监会《关于在上市公司建立独立董事制度的指导 意见》，对公司有关事项发表独立意见，具体如下： 1.2023 年 1 月 9 日，对关于公司限制性股票激励计划第二个解锁期解锁条 件成就、关于回购注销部分限制性股票等事项发表了独立意见。 2.2023 年 3 月 16 日，对关于公司聘任高级管理人员、关于公司开展 2023 年度期货套期保值业务、关于为中粮生化（泰国） ...

Financial Performance - COFCO Biotech achieved a revenue of RMB 1.2 billion in 2023, representing a year-on-year growth of 15%[25] - The company reported a net profit of RMB 300 million, an increase of 20% compared to the previous year[25] - In 2023, the company's operating revenue reached ¥20,378,950,091.78, representing a 2.31% increase compared to ¥19,918,051,356.78 in 2022[38] - The net profit attributable to shareholders was -¥601,629,843.35 in 2023, a decrease of 156.84% from ¥1,058,864,667.31 in 2022[38] - The net cash flow from operating activities increased by 176.38% to ¥1,957,978,669.51 in 2023, compared to ¥708,442,677.10 in 2022[38] - The total revenue for the year reached ¥20,378,950,101.78, an increase of 9.00% compared to ¥18,688,563,193.38 in the previous year[70] - The net profit attributable to shareholders of the listed company was ¥1,450,089.28 in Q1, but showed a loss of ¥336,693,730.46 in Q2, followed by a profit of ¥2,376,698.22 in Q3, and a loss of ¥268,762,900.39 in Q4[63] - The main business cost for fuel ethanol and its by-products was ¥9,382,635,260.29, accounting for 48.73% of total operating costs, which increased by 18.03% from the previous year[73] - The company reported a significant increase in government subsidies, amounting to ¥44,560,921.11, compared to ¥485,715,881.00 in the previous year[64] Market Expansion and Product Development - User data showed an increase in active users by 25%, reaching a total of 5 million[25] - The company plans to launch two new products in the next quarter, targeting a market expansion of 10%[25] - Future guidance indicates a projected revenue growth of 12% for 2024, driven by new product launches and market expansion[25] - The company is actively promoting a diversified raw material strategy for fuel ethanol production, utilizing corn, cassava, and non-edible rice and wheat[90] - The market for biodegradable materials is expected to exceed 1 million tons by 2026, indicating significant future growth potential[86] - New product development includes the introduction of plant-based protein products, which are expected to capture a growing segment of the health-conscious consumer market[183] - The company is planning to expand its market presence in Southeast Asia, targeting a 25% increase in market share within the next three years[183] Research and Development - COFCO Biotech is investing RMB 200 million in R&D for new technologies in biofuels and biochemical products[25] - R&D personnel decreased from 460 in 2022 to 422 in 2023, a reduction of 8.26%[80] - The proportion of R&D personnel in the company decreased from 5.79% in 2022 to 5.52% in 2023, a decline of 0.27%[80] - The company’s R&D investment amounted to CNY 164,391,170.21 in 2023, up 24.28% from 2022[95] - The company has authorized a total of 601 patents and participated in the formulation of over 100 standards as of the end of 2023[103] - The company is focusing on continuous R&D innovation, particularly in functional sugars and specialty syrups for various food and beverage applications[155] Environmental Compliance and Sustainability - The company emphasizes a commitment to sustainability and plans to reduce carbon emissions by 15% over the next three years[25] - The company has implemented advanced treatment processes such as anaerobic and aerobic treatment, achieving stable discharge standards[43] - The company is committed to utilizing qualified third-party services for waste disposal and treatment[43] - The company reported a COD level of 192 mg/L and ammonia nitrogen of 17 mg/L, indicating compliance with environmental standards[57] - The company has implemented a wet desulfurization process and SNCR denitrification technology to manage air pollutants effectively[58] - The company is committed to environmental sustainability and compliance with industry emission standards[53] - The company aims to achieve a 30% reduction in carbon emissions by 2025 as part of its sustainability initiatives[183] Governance and Management - The company has established a comprehensive internal control system to ensure effective governance and compliance with regulatory standards[163] - The company maintained a commitment to transparency and accountability in its governance practices[200] - The company’s board of directors includes independent directors and a supervisory committee, ensuring compliance and governance[177] - The company has a diverse management team with members ranging in age from 35 to 65, indicating a mix of experience and youth[177] - The company experienced several resignations, including the departure of Yin Jianhao as chairman on December 15, 2023, and Zhang Jianhua as supervisor on May 29, 2023[179] Operational Efficiency - The company has completed key projects in 2023, enhancing its market competitiveness, including the flexible production transformation project and the alcohol industry chain upgrade project[104] - The company is focused on expanding its market presence by increasing sales of specialty starch and ethanol products, while also enhancing service quality for strategic customers in the fuel ethanol sector[147] - The company will optimize its procurement strategy by diversifying raw materials and enhancing centralized procurement to reduce costs, including leveraging corn import quotas and seeking alternative sourcing opportunities[144] - The company has established strategic partnerships with multiple coal mining enterprises to enhance procurement efficiency and reduce costs[119] Challenges and Risks - Risks identified include significant product price fluctuations and intense market competition, as well as risks related to new product development and regulatory policies[156] - The company has not engaged in speculative derivative investments during the reporting period[131] - The company experienced a substantial asset impairment of ¥593,578,531.03, representing 109.41% of total profit, mainly due to indications of inventory impairment[107]

报告导读 本报告是中粮生物科技股份有限公司发布的第 2 份环境、社会及管治（ESG）报告。本着客观、规范、透明和全面的原则， 报告详细披露了 2023 年公司在环境、社会和公司治理等方面的履责情况。 组织范围 报告获取 读者可通过深圳证券交易所官网 https://www.szse.cn/index/index.html 获取本报告电子版。如您对公 司环境、社会及公司治理方面的披露和表现有任何意见或建议，请通过以下方式与我们取得联系： 地址：北京市朝阳区朝阳门南大街兆泰国际中心 A 座 22 层 邮编：100020 电话：010--6504 7979 传真：010--6504 7878 时间范围 2023 年 1 月 1 日 至 12 月 31 日， 为 增 强 报告完整性和可比性，部分内容有所延伸。 编制依据 数据说明及可靠性保证 本报告所引用数据均来自公司正式文件 和统计报告，并经相关部门审核。公司 承诺本报告不存在任何虚假记载、误导 性陈述，并对其内容真实性、准确性和 完整性负责。 中粮生物科技股份有限公司及其所属企业。为便 于表述和阅读，报告中以"中粮生物科技""中 粮科技""公司""我们"指称中粮生 ...

安徽淮河律师事务所 关于中粮生物科技股份有限公司 限制性股票激励计划部分限制性股票回购并注销事项的 法 律 意 见 书 淮河证字〔2024〕第 1 号 地址：安徽省蚌埠市燕山路 968 号冠宜大厦 1 号楼 20 层 电话：0552-2835900 传真：0552-2835903 网址：http://www.hhls.net 安徽淮河律师事务所 关于中粮生物科技股份有限公司 限制性股票激励计划部分限制性股票回购并注销事项的 法律意见书 淮河证字〔2024〕第 1 号 致：中粮生物科技股份有限公司 安徽淮河律师事务所（以下简称本所）接受中粮生物科技股份有 限公司（以下简称公司或中粮科技）的委托，担任公司实施限制性股 票激励计划（以下简称股票激励计划）的专项法律顾问。本所律师根 据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民 共和国证券法》（以下简称《证券法》）、中国证券监督管理委员会 （以下简称中国证监会）发布的《上市公司股权激励管理办法》（以 下简称《管理办法》）等法律、法规和规范性文件和《中粮生物科技 股份有限公司章程》（以下简称《公司章程》）的规定，对公司根据 《中粮生物科技股份有限公司限制 ...

公司委托天职国际会计师事务所(特殊普通合伙)对 2023 年度会计报表进行 审计。经审计，认为本公司 2023 年度会计报表已经按照新会计准则的规定编制， 在所有重大方面公允地反映了公司 2023 年度的财务状况、经营成果和现金流量。 天职国际会计师事务所(特殊普通合伙)为本公司 2023 年度财务报告出具了标准 无保留意见的财务审计报告。 证券代码：000930 证券简称：中粮科技 公告编号：2024-023 中粮生物科技股份有限公司 2023 年度财务决算报告 一、主要财务指标情况 单位：万元 | 项 目 | 本年累计 | 上年同期 | 增 减 | | --- | --- | --- | --- | | 营业收入 | 2,037,895.01 | 1,991,805.14 | 2.31% | | 利润总额 | -54,253.96 | 135,988.81 | -139.90% | | 净利润 | -61,629.19 | 106,061.15 | -158.11% | | 归属于上市公司股东的净利润 | -60,162.98 | 105,852.93 | -156.84% | | 经营活动产生的现金流量 ...

目 录 内 部 控 制 审 计 报 告 1 中 粮 生 物科 技 股份 有 限 公司 内 部 控 制审 计 报告 天职业字[2024]23009-4 号 中粮生物科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了中粮生物科技 股份有限公司（以下简称"中粮科技"）2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》的规定，建 立健全和有效实施内部控制，并评价其有效性是中粮科技董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见，并对注意到 的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制审计报告 天职业字[2024]23009-4 号 内部控制审计报告（续） 天职业字[2024]23009-4 号 [此页无正文] 中国注册会计师： 解小雨 中国·北京 二○二四年四月二十三日 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化可能导致内 ...

Financial Performance - Total operating revenue for the current period reached ¥4,731,528,010.13, an increase from ¥4,522,104,000.26 in the previous period, representing a growth of approximately 4.63%[1] - Total operating costs amounted to ¥4,609,751,181.02, compared to ¥4,510,275,709.94 in the prior period, reflecting an increase of about 2.66%[1] - Net profit for the current period was ¥24,640,657.00, significantly up from ¥3,617,226.21 in the previous period, indicating a growth of approximately 582.56%[4] - Basic earnings per share increased to ¥0.0134 from ¥0.0008, marking a substantial rise of 1,575%[6] - Other income for the current period was ¥10,720,888.76, up from ¥9,045,836.49, indicating an increase of approximately 18.54%[4] - Net profit attributable to shareholders was ¥24,840,311.23, a significant increase of 1,613.02% from ¥1,450,089.28 year-on-year[26] - The weighted average return on equity was 0.24%, up from 0.01% in the previous year[26] Cash Flow - Cash inflow from operating activities totaled ¥5,929,009,821.95, down from ¥6,453,391,228.69 in the previous period, a decrease of about 8.09%[7] - Cash outflow from operating activities was ¥7,343,594,351.67, compared to ¥9,134,605,592.15 in the prior period, showing a decrease of approximately 19.63%[7] - The net cash flow from operating activities improved by 47.24%, amounting to -¥1,414,584,529.72 compared to -¥2,681,214,363.46 in the previous year[31] - The net cash flow from investing activities was -280,692,622.61, a decline from -231,346,407.87 in the prior period[38] - Cash inflow from financing activities totaled 2,740,258,981.40, down from 3,693,238,000.00 in the previous period[38] - The net cash flow from financing activities was 1,504,712,206.77, significantly lower than 3,042,507,094.32 in the prior period[38] - The cash and cash equivalents at the end of the period amounted to 1,264,274,022.80, compared to 1,145,935,878.88 at the end of the previous period[38] Assets and Liabilities - The total assets of COFCO Biotech reached RMB 18,053,837,163.20, an increase from RMB 16,557,861,385.94 in the previous period, reflecting a growth of approximately 9.0%[19] - Current assets totaled RMB 7,616,694,519.53, up from RMB 6,035,315,718.36, indicating a growth of about 26.3%[19] - The total liabilities amounted to RMB 6,726,048,170.02, up from RMB 5,141,805,247.60, indicating an increase of approximately 31.0%[19] - The company's non-current assets totaled RMB 10,437,142,643.67, a slight decrease from RMB 10,522,545,667.58, reflecting a decline of about 0.8%[19] - The total equity attributable to shareholders was ¥10,419,474,802.16, a slight decrease of 0.31% from ¥10,451,611,345.75[26] Research and Development - Research and development expenses increased to ¥30,614,055.85 from ¥25,614,065.15, representing a growth of about 19.06%[1] - The company's R&D expenses increased by 19.52% to ¥30,614,055.85, up from ¥25,614,065.15 in the same period last year[31] Shareholder Information - The company reported no significant changes in the top 10 shareholders' financing activities during the period[14] - COFCO Biotech's major shareholder, COFCO Bio-chemical Investment Co., Ltd., holds a significant stake without any reported related party transactions[14] - The company had a total of 117,703 common shareholders at the end of the reporting period[32] Inventory and Borrowings - Inventory increased significantly to RMB 3,399,208,050.24 from RMB 2,534,268,489.13, representing a growth of around 34.1%[19] - Short-term borrowings rose to RMB 4,772,971,429.85 from RMB 3,216,804,597.02, an increase of approximately 48.3%[19] Financial Changes - The company reported a decrease in financial expenses by 69.02%, amounting to ¥10,340,921.89, due to a reduction in loan scale[31] - The total comprehensive income attributable to the parent company was ¥-28,040,772.21, compared to ¥-7,978,934.33 in the prior period, reflecting a decline[6] - The impact of exchange rate changes on cash and cash equivalents was -24,207,445.69, contrasting with a positive impact of 409,736.55 in the previous period[38]

中 粮 生 物科 技 股份 有 限 公司 审计报告 天职业字[2024]23009 号 目 录 审计报告 1 2023 年度财务报表 6 2023 年度财务报表附注 18 审计报告 天职业字[2024]23009 号 中粮生物科技股份有限公司全体股东： 一、审计意见 我们审计了后附的中粮生物科技股份有限公司（以下简称"中粮科技"）财务报表，包 括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润表、合并及 母公司现金流量表、合并及母公司所有者权益变动表，以及财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了 中粮科技 2023 年 12 月 31 日的合并及母公司财务状况以及 2023 年度的合并及母公司经营成 果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业道德守则，我们独立于中粮科技，并履行了职业道德方面的其他责任。我们相信，我们获 取的审计证据是充分、适当的，为发表审计 ...